


Cancer Trials Ireland features at SABCS's 40th Anniversary

Andrés Hernando, Clinical Project Manager, Cancer Trials Ireland and Breast DSSG Operations Lead.

San Antonio Breast Cancer Symposium (SABCS), one of the most important international scientific events in breast cancer, celebrated its 40th Anniversary last year. Over 7,000 people from more than 90 countries attended the landmark symposium; up to 40 of them from Ireland.


Although there were no practice-changing studies presented at the symposium, several studies presented, some of which Cancer Trials Ireland actively participated, provided key points to better understand breast cancer and how best to treat it.

The first is the NSABP B-47 (CTRIAL-IE 11-24) study (GS1-02) that compared adjuvant chemotherapy with or without trastuzumab for 1 year in high-risk, invasive breast cancer negative for HER2 by ISH and with IHC 1+ or 2+ (HER2-Low IBC). The main conclusion was that there is no benefit to trastuzumab therapy in this setting. Prof John Crown was a co-author of this trial.




NSABP B-47 presentation by Louis Fehrenbacher, MD of Kaiser Permanente, Northern California.

Another presentation was an update on the results of the SOFT (CTRIAL-IE 06-02) trial (GS4-03) that compared adjuvant tamoxifen with or without ovarian function suppression in premenopausal women with hormone receptor-positive early breast cancer. The results with an additional follow-up of a median of 8 years support the value of ovarian function suppression for some premenopausal women. Cancer Trials Ireland contributed to the study's patient recruitment.



SOFT presentation by Gini Fleming, MD of The University of Chicago Medicine.

In the area of metastatic cancer, the EMBRACA (CTRIAL-IE 14-01) results (GS6-07) were presented. It found that Talazoparib significantly prolonged progression free survival in HER2-negative advanced breast cancer and a germline BRCA mutation. Cancer Trials Ireland participated in patient recruitment for this study.



EMBRACA presentation by Jennifer Litton, MD of The University of Texas M.D. Anderson Cancer Center

It should be noted that the number of trials with immunotherapy has increased over the past years and currently there are trials in both early and metastatic disease as well as combinations of treatments (e.g. alternate chemotherapy, with PARP inhibitors, with CDK4/6 inhibitors.).

As a summary of the Symposium I would like to highlight that nine abstracts were submitted to SABCS in which Cancer Trials Ireland was represented among the authors. One oral presentation (NSABP B-47) (CTRIAL-IE 11-24); two poster discussion (BIG 02-98 (PD6-07) (ICORG 98-01) and EORTC 10085 (ICORG 12-40) (PD7-12)); and 6 posters (IBCSG 42-12/BIG 2-12 SNAP (P5-18-02) (CTRIAL-IE 12-45), PALOMA-2 (P5-19-01 and P5-21-25) (CTRIAL-IE 09-01), CXCL16/CXCR6 expression in HER2+ BC (P5-11-03) (CTRIAL-IE 10-05), pregnancy associated breast cancer study (P6-08-17) and PanTHER (OT3-06-05)



(CTRIAL-IE 15-02).

Dr Niamh Keegan and Dr Patrick Morris, Beaumont Hospital, with the PanTHER poster presentation. Prof Bryan Hennessy is the Principal Investigator on this trial.

Another key purpose of this Symposium was to make contact with colleagues and collaborators from other research groups and create the connections that could lead to future collaborations. Meetings with the Spanish Breast Cancer Research Group (GEICAM), Translational Research in Oncology (TRIO) and Fondazione Michelangelo were